NDDS in Cancer Therapy Market - Global Forecast 2026-2032

Nanoparticle drug delivery systems are transforming cancer therapy by providing highly targeted treatment approaches that enhance clinical outcomes and operational efficiency. In this evolving market, senior decision-makers require actionable intelligence to navigate technology advancements, investment trends, and shifting regulatory landscapes in the NDDS in Cancer Therapy Market.

Market Snapshot: NDDS in Cancer Therapy Market

The NDDS in Cancer Therapy Market achieved significant growth, increasing from USD 13.35 billion in 2025 to USD 15.18 billion in 2026, with projections reaching USD 32.90 billion by 2032. This represents a CAGR of 13.74%, reflecting accelerated adoption of advanced delivery technologies and the ongoing development of nanoparticle-enabled oncology treatments. Market expansion is being driven by greater precision in disease targeting and improved patient tolerability, which continue to attract investments from biopharmaceutical organizations, contract development and manufacturing organizations (CDMOs), and diagnostics innovators. Strong clinical and commercial performance has established nanoparticle drug delivery as a key focus area for the oncology segment.

Scope & Segmentation

This report delivers a detailed and structured analysis of the NDDS in Cancer Therapy Market, illustrating how evolving platform technologies and regional trends influence the market’s commercial potential and regulatory trajectories. Segmentation enables stakeholders to clearly assess the dynamics that shape competitive positioning across the sector.

Product Types: Dendrimers, exosomes, lipid nanocarriers, liposomes, metallic nanoparticles, micelles, nanoemulsions, polymeric nanoparticles
Drug Modalities: Gene therapy agents, monoclonal antibodies, oligonucleotides, siRNA, chemotherapeutics
Clinical Applications: Chemotherapy, immunotherapy, photodynamic therapy, radiotherapy, targeted therapies
Technology Platforms: Implantable depots, injectable suspensions, microneedle systems, nanotechnology-based approaches that support both active and passive targeting
Regional Coverage: Americas, Europe Middle East & Africa, Asia-Pacific

This segmentation framework supports decision-makers in comparing diverse technology pathways and risk mitigation options while addressing regulatory, formulation, and market-entry hurdles unique to each product type and region. Understanding these segments accelerates the identification of commercialization opportunities and supports informed investment.

Key Takeaways: Strategic Insights for NDDS in Cancer Therapy Market

Flexible and modular technology platforms enable the rapid development of therapies tailored to specific clinical requirements and facilitate integration with diverse payloads for multiple oncology indications.
The shift towards precision medicine and biomarker-based designs is optimizing candidate selection processes and reducing the duration from research to clinic for nanoparticle-based therapies.
Maintaining scalable manufacturing processes with consistent batch quality remains a significant challenge, demanding close collaboration across R&D, regulatory, and operations teams to ensure product integrity.
Successful clinical translation and commercial delivery increasingly depend on alliances linking technology providers, academic institutions, and contract partners to enable seamless knowledge and resource sharing.
Payers and healthcare systems now expect compelling real-world outcomes and robust health economics data to justify adoption and reimbursement of new oncology therapies built on nanoparticle delivery platforms.
Regional variation in regulatory environments, clinical infrastructure, and payer systems means go-to-market strategies must be tailored to local market realities for sustainable success.

Tariff Impact on Supply Chains

Recent tariff adjustments in the United States have changed the cost structure for sourcing essential raw materials and components used in nanoparticle drug delivery systems. In response, organizations are revisiting their procurement models, qualifying additional domestic and alternative suppliers, and exploring the benefits of localized manufacturing. These evolving supply strategies are reshaping capital allocation, supply chain resilience, and long-term operational risk profiles for biopharmaceutical and technology firms operating in this field.

Methodology & Data Sources

The insights in this report are drawn from structured expert interviews, comprehensive literature reviews, patent scrutiny, and in-depth discussions with manufacturing leaders. By triangulating qualitative observations with market data and registry analytics, the research ensures findings are current, reliable, and highly relevant to senior stakeholders seeking to navigate the NDDS in Cancer Therapy Market.

Why This Report Matters

Empowers executive teams to benchmark nanoparticle-enabled oncology products, platform advances, and regional growth strategies.
Guides procurement and operational leaders by mapping supply chain exposures, tariff risks, and critical material dependencies across the value chain.
Supports commercial, clinical, and regulatory decision-makers in accelerating market entry and payer access for novel oncology therapies leveraging nanoparticle drug delivery platforms.

Conclusion

This report gives decision-makers a practical roadmap for aligning innovation, regulatory compliance, and commercial execution in the NDDS in Cancer Therapy Market. Leveraging these insights will support sustainable clinical differentiation and operational advantage in a rapidly progressing field.

Additional Product Information:

Purchase of this report includes 1 year online access with quarterly updates.
This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

1. Preface

1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders

2. Research Methodology

2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations

3. Executive Summary

3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. Market Share Analysis, 2025
3.5. FPNV Positioning Matrix, 2025
3.6. New Revenue Opportunities
3.7. Next-Generation Business Models
3.8. Industry Roadmap

4. Market Overview

4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Porter’s Five Forces Analysis
4.4. PESTLE Analysis
4.5. Market Outlook
4.5.1. Near-Term Market Outlook (0-2 Years)
4.5.2. Medium-Term Market Outlook (3-5 Years)
4.5.3. Long-Term Market Outlook (5-10 Years)
4.6. Go-to-Market Strategy

5. Market Insights

5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025
7. Cumulative Impact of Artificial Intelligence 2025

8. NDDS in Cancer Therapy Market, by Product Type

8.1. Dendrimers
8.2. Exosomes
8.3. Lipid Nanocarriers
8.4. Liposomes
8.5. Metallic Nanoparticles
8.6. Micelles
8.7. Nanoemulsions
8.8. Polymeric Nanoparticles

9. NDDS in Cancer Therapy Market, by Drug Type

9.1. Gene Therapy Agents
9.2. Monoclonal Antibodies
9.3. Oligonucleotide Drugs
9.4. SiRNA
9.5. Small-Molecule Chemotherapeutics

10. NDDS in Cancer Therapy Market, by Technology Platform

10.1. Implantable Depot Systems
10.2. Injectable Suspensions
10.3. Microneedle Systems
10.4. Nanotechnology

11. NDDS in Cancer Therapy Market, by Application

11.1. Chemotherapy
11.2. Immunotherapy
11.3. Photodynamic Therapy
11.4. Radiotherapy
11.5. Targeted Therapy

12. NDDS in Cancer Therapy Market, by Region

12.1. Americas
12.1.1. North America
12.1.2. Latin America
12.2. Europe, Middle East & Africa
12.2.1. Europe
12.2.2. Middle East
12.2.3. Africa
12.3. Asia-Pacific

13. NDDS in Cancer Therapy Market, by Group

13.1. ASEAN
13.2. GCC
13.3. European Union
13.4. BRICS
13.5. G7
13.6. NATO

14. NDDS in Cancer Therapy Market, by Country

14.1. United States
14.2. Canada
14.3. Mexico
14.4. Brazil
14.5. United Kingdom
14.6. Germany
14.7. France
14.8. Russia
14.9. Italy
14.10. Spain
14.11. China
14.12. India
14.13. Japan
14.14. Australia
14.15. South Korea

15. United States NDDS in Cancer Therapy Market
16. China NDDS in Cancer Therapy Market

17. Competitive Landscape

17.1. Market Concentration Analysis, 2025
17.1.1. Concentration Ratio (CR)
17.1.2. Herfindahl Hirschman Index (HHI)
17.2. Recent Developments & Impact Analysis, 2025
17.3. Product Portfolio Analysis, 2025
17.4. Benchmarking Analysis, 2025
17.5. AbbVie Inc.
17.6. Amgen Inc.
17.7. AstraZeneca PLC
17.8. Bristol-Myers Squibb Company
17.9. F. Hoffmann-La Roche Ltd
17.10. Johnson & Johnson
17.11. Merck & Co., Inc.
17.12. Novartis AG
17.13. Pfizer Inc.
17.14. Samyang Holdings Corporation
17.15. Sanofi S.A.
17.16. Teva Pharmaceutical Industries Ltd.
17.17. West Pharmaceutical Services, Inc.

List of Figures

FIGURE 1. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 2. GLOBAL NDDS IN CANCER THERAPY MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 3. GLOBAL NDDS IN CANCER THERAPY MARKET, FPNV POSITIONING MATRIX, 2025
FIGURE 4. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 5. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY DRUG TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 6. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY TECHNOLOGY PLATFORM, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 7. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 9. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 11. UNITED STATES NDDS IN CANCER THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 12. CHINA NDDS IN CANCER THERAPY MARKET SIZE, 2018-2032 (USD MILLION)

List of Tables

TABLE 1. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 2. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 3. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY DENDRIMERS, BY REGION, 2018-2032 (USD MILLION)
TABLE 4. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY DENDRIMERS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 5. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY DENDRIMERS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 6. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY EXOSOMES, BY REGION, 2018-2032 (USD MILLION)
TABLE 7. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY EXOSOMES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 8. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY EXOSOMES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 9. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY LIPID NANOCARRIERS, BY REGION, 2018-2032 (USD MILLION)
TABLE 10. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY LIPID NANOCARRIERS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 11. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY LIPID NANOCARRIERS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 12. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY LIPOSOMES, BY REGION, 2018-2032 (USD MILLION)
TABLE 13. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY LIPOSOMES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 14. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY LIPOSOMES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 15. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY METALLIC NANOPARTICLES, BY REGION, 2018-2032 (USD MILLION)
TABLE 16. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY METALLIC NANOPARTICLES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 17. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY METALLIC NANOPARTICLES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 18. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY MICELLES, BY REGION, 2018-2032 (USD MILLION)
TABLE 19. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY MICELLES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 20. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY MICELLES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 21. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY NANOEMULSIONS, BY REGION, 2018-2032 (USD MILLION)
TABLE 22. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY NANOEMULSIONS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 23. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY NANOEMULSIONS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 24. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY POLYMERIC NANOPARTICLES, BY REGION, 2018-2032 (USD MILLION)
TABLE 25. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY POLYMERIC NANOPARTICLES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 26. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY POLYMERIC NANOPARTICLES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 27. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
TABLE 28. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY GENE THERAPY AGENTS, BY REGION, 2018-2032 (USD MILLION)
TABLE 29. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY GENE THERAPY AGENTS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 30. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY GENE THERAPY AGENTS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 31. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2032 (USD MILLION)
TABLE 32. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 33. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 34. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY OLIGONUCLEOTIDE DRUGS, BY REGION, 2018-2032 (USD MILLION)
TABLE 35. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY OLIGONUCLEOTIDE DRUGS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 36. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY OLIGONUCLEOTIDE DRUGS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 37. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY SIRNA, BY REGION, 2018-2032 (USD MILLION)
TABLE 38. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY SIRNA, BY GROUP, 2018-2032 (USD MILLION)
TABLE 39. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY SIRNA, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 40. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY SMALL-MOLECULE CHEMOTHERAPEUTICS, BY REGION, 2018-2032 (USD MILLION)
TABLE 41. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY SMALL-MOLECULE CHEMOTHERAPEUTICS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 42. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY SMALL-MOLECULE CHEMOTHERAPEUTICS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 43. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
TABLE 44. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY IMPLANTABLE DEPOT SYSTEMS, BY REGION, 2018-2032 (USD MILLION)
TABLE 45. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY IMPLANTABLE DEPOT SYSTEMS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 46. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY IMPLANTABLE DEPOT SYSTEMS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 47. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY INJECTABLE SUSPENSIONS, BY REGION, 2018-2032 (USD MILLION)
TABLE 48. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY INJECTABLE SUSPENSIONS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 49. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY INJECTABLE SUSPENSIONS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 50. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY MICRONEEDLE SYSTEMS, BY REGION, 2018-2032 (USD MILLION)
TABLE 51. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY MICRONEEDLE SYSTEMS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 52. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY MICRONEEDLE SYSTEMS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 53. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY NANOTECHNOLOGY, BY REGION, 2018-2032 (USD MILLION)
TABLE 54. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY NANOTECHNOLOGY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 55. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY NANOTECHNOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 56. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 57. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2032 (USD MILLION)
TABLE 58. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY CHEMOTHERAPY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 59. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY CHEMOTHERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 60. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2018-2032 (USD MILLION)
TABLE 61. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY IMMUNOTHERAPY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 62. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY IMMUNOTHERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 63. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY PHOTODYNAMIC THERAPY, BY REGION, 2018-2032 (USD MILLION)
TABLE 64. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY PHOTODYNAMIC THERAPY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 65. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY PHOTODYNAMIC THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 66. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY RADIOTHERAPY, BY REGION, 2018-2032 (USD MILLION)
TABLE 67. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY RADIOTHERAPY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 68. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY RADIOTHERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 69. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2018-2032 (USD MILLION)
TABLE 70. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY TARGETED THERAPY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 71. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY TARGETED THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 72. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 73. AMERICAS NDDS IN CANCER THERAPY MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 74. AMERICAS NDDS IN CANCER THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 75. AMERICAS NDDS IN CANCER THERAPY MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
TABLE 76. AMERICAS NDDS IN CANCER THERAPY MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
TABLE 77. AMERICAS NDDS IN CANCER THERAPY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 78. NORTH AMERICA NDDS IN CANCER THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 79. NORTH AMERICA NDDS IN CANCER THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 80. NORTH AMERICA NDDS IN CANCER THERAPY MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
TABLE 81. NORTH AMERICA NDDS IN CANCER THERAPY MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
TABLE 82. NORTH AMERICA NDDS IN CANCER THERAPY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 83. LATIN AMERICA NDDS IN CANCER THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 84. LATIN AMERICA NDDS IN CANCER THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 85. LATIN AMERICA NDDS IN CANCER THERAPY MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
TABLE 86. LATIN AMERICA NDDS IN CANCER THERAPY MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
TABLE 87. LATIN AMERICA NDDS IN CANCER THERAPY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 88. EUROPE, MIDDLE EAST & AFRICA NDDS IN CANCER THERAPY MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 89. EUROPE, MIDDLE EAST & AFRICA NDDS IN CANCER THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 90. EUROPE, MIDDLE EAST & AFRICA NDDS IN CANCER THERAPY MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
TABLE 91. EUROPE, MIDDLE EAST & AFRICA NDDS IN CANCER THERAPY MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
TABLE 92. EUROPE, MIDDLE EAST & AFRICA NDDS IN CANCER THERAPY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 93. EUROPE NDDS IN CANCER THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 94. EUROPE NDDS IN CANCER THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 95. EUROPE NDDS IN CANCER THERAPY MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
TABLE 96. EUROPE NDDS IN CANCER THERAPY MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
TABLE 97. EUROPE NDDS IN CANCER THERAPY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 98. MIDDLE EAST NDDS IN CANCER THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 99. MIDDLE EAST NDDS IN CANCER THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 100. MIDDLE EAST NDDS IN CANCER THERAPY MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
TABLE 101. MIDDLE EAST NDDS IN CANCER THERAPY MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
TABLE 102. MIDDLE EAST NDDS IN CANCER THERAPY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 103. AFRICA NDDS IN CANCER THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 104. AFRICA NDDS IN CANCER THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 105. AFRICA NDDS IN CANCER THERAPY MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
TABLE 106. AFRICA NDDS IN CANCER THERAPY MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
TABLE 107. AFRICA NDDS IN CANCER THERAPY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 108. ASIA-PACIFIC NDDS IN CANCER THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 109. ASIA-PACIFIC NDDS IN CANCER THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 110. ASIA-PACIFIC NDDS IN CANCER THERAPY MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
TABLE 111. ASIA-PACIFIC NDDS IN CANCER THERAPY MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
TABLE 112. ASIA-PACIFIC NDDS IN CANCER THERAPY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 113. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 114. ASEAN NDDS IN CANCER THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 115. ASEAN NDDS IN CANCER THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 116. ASEAN NDDS IN CANCER THERAPY MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
TABLE 117. ASEAN NDDS IN CANCER THERAPY MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
TABLE 118. ASEAN NDDS IN CANCER THERAPY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 119. GCC NDDS IN CANCER THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 120. GCC NDDS IN CANCER THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 121. GCC NDDS IN CANCER THERAPY MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
TABLE 122. GCC NDDS IN CANCER THERAPY MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
TABLE 123. GCC NDDS IN CANCER THERAPY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 124. EUROPEAN UNION NDDS IN CANCER THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 125. EUROPEAN UNION NDDS IN CANCER THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 126. EUROPEAN UNION NDDS IN CANCER THERAPY MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
TABLE 127. EUROPEAN UNION NDDS IN CANCER THERAPY MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
TABLE 128. EUROPEAN UNION NDDS IN CANCER THERAPY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 129. BRICS NDDS IN CANCER THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 130. BRICS NDDS IN CANCER THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 131. BRICS NDDS IN CANCER THERAPY MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
TABLE 132. BRICS NDDS IN CANCER THERAPY MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
TABLE 133. BRICS NDDS IN CANCER THERAPY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 134. G7 NDDS IN CANCER THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 135. G7 NDDS IN CANCER THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 136. G7 NDDS IN CANCER THERAPY MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
TABLE 137. G7 NDDS IN CANCER THERAPY MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
TABLE 138. G7 NDDS IN CANCER THERAPY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 139. NATO NDDS IN CANCER THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 140. NATO NDDS IN CANCER THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 141. NATO NDDS IN CANCER THERAPY MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
TABLE 142. NATO NDDS IN CANCER THERAPY MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
TABLE 143. NATO NDDS IN CANCER THERAPY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 144. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 145. UNITED STATES NDDS IN CANCER THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 146. UNITED STATES NDDS IN CANCER THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 147. UNITED STATES NDDS IN CANCER THERAPY MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
TABLE 148. UNITED STATES NDDS IN CANCER THERAPY MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
TABLE 149. UNITED STATES NDDS IN CANCER THERAPY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 150. CHINA NDDS IN CANCER THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 151. CHINA NDDS IN CANCER THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 152. CHINA NDDS IN CANCER THERAPY MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
TABLE 153. CHINA NDDS IN CANCER THERAPY MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
TABLE 154. CHINA NDDS IN CANCER THERAPY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)

Companies Mentioned

The key companies profiled in this NDDS in Cancer Therapy market report include:

AbbVie Inc.
Amgen Inc.
AstraZeneca PLC
Bristol-Myers Squibb Company
F. Hoffmann-La Roche Ltd
Johnson & Johnson
Merck & Co., Inc.
Novartis AG
Pfizer Inc.
Samyang Holdings Corporation
Sanofi S.A.
Teva Pharmaceutical Industries Ltd.
West Pharmaceutical Services, Inc.

Table Information

Report Attribute	Details
No. of Pages	185
Published	January 2026
Forecast Period	2026 - 2032
Estimated Market Value ( USD ) in 2026	$ 15.18 Billion
Forecasted Market Value ( USD ) by 2032	$ 32.9 Billion
Compound Annual Growth Rate	13.7%
Regions Covered	Global
No. of Companies Mentioned	14

License	Properties	Price
SINGLE USER LICENSE PDF, Excel and Online Access	This is a single user license, allowing one user access to the product.	€3471EUR$3,939USD£3,022GBP
1 - 5 USER LICENSE PDF, Excel and Online Access	This is a 1-5 user license, allowing up to five users have access to the product.	€3745EUR$4,249USD£3,259GBP
SITE LICENSE PDF, Excel and Online Access	This is a site license, allowing all users within a given geographical location of your organization access to the product.	€5075EUR$5,759USD£4,418GBP
ENTERPRISE LICENSE PDF, Excel and Online Access	This is an enterprise license, allowing all employees within your organization access to the product.	€6142EUR$6,969USD£5,346GBP

Market Snapshot: NDDS in Cancer Therapy Market

Scope & Segmentation

Key Takeaways: Strategic Insights for NDDS in Cancer Therapy Market

Tariff Impact on Supply Chains

Methodology & Data Sources

Why This Report Matters

Conclusion

Table of Contents

Companies Mentioned

Table Information

Related Topics

Related Reports

Novel Drug Delivery Systems in Cancer Therapy - Global Strategic Business Report

NDDS Cancer Therapy Market Report: Trends, Forecast and Competitive Analysis to 2031

Nanotechnology in Cancer Treatment Market Report 2025

NDDS in Cancer Therapy - Global Strategic Business Report

Nanotechnology in Cancer Treatment: Technologies and Global Markets